Session Information
2012 Summer Meeting
Click here to go to the previous page
Clinical Impact of MRSA Bacteremia with Reduced Vancomycin Susceptibility
Track:
Education Sessions (CE)
Program Code: 114-L01
Date: Wednesday, June 13, 2012
Time: 8:00 AM to 10:30 AM EST
Location:
327, Level 300
PRESENTER(S):
Dr. Tonya Crawford, PharmD, BCPS, Assistant Professor of Clinical Sciences, Roosevelt University
PROGRAM CHAIR:
Dr. Tonya Crawford, PharmD, BCPS, Assistant Professor of Clinical Sciences, Roosevelt University
Description
In this session, experts will 1) review the susceptibility methods utilized to detect vancomycin MICs, 2) define predicative factors of MRSA blood isolates with high vancomycin MICs, 3) compare and contrast outcomes of patient diagnosed with MRSA bacteremia with high vancomycin MICs to those with low, and 4) evaluate other therapeutic options to treat MRSA bacteremia. At the conclusion, attendees will have a better understanding of how to appropriately manage patients diagnosed with MRSA bacteremia with high vancomycin MICs.
LEARNER OUTCOMES:
- Analyze the difference in clinical outcomes of patients with MRSA bacteremia with high vancomycin MICs to those with low vancomycin MICs.
- Define predicative factors of the development of MRSA bacteremia with high (defined as 1.5 g/mL) vancomycin MICs.
- Discuss challenges and realities when implementing these concepts in your institution.
- Distinguish susceptibility methods utilized to detect vancomycin MICs.
- Evaluate other treatment options with MRSA activity to treat MRSA bacteremia with high vancomycin MICs.
Handout Online
